Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The short-squeeze rally in meme stocks like GameStop (NYSE: GME ) and AMC Entertainment (NYSE: AMC ) is poised to go down in financial history books in terms of shareholder gains. However, a short squeeze is onl...
Thanumporn Thongkongkaew/iStock via Getty Images S3 Partners updates on the U.S. stocks with the highest percentage of short interest as the calendar turns to the second half of the year. While the average short interest as a percentage of total float for a U.S. stock is 5.39%, the list of na...
Esperion Therapeutics (ESPR) announces the appointment of JoAnne Foody as the company's chief medical officer, effective immediately.Foody brings more than 20 years of experience in academic and preventive cardiology to Esperion.She joins ESPERION after six years with John...
ANN ARBOR, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately. She will serve as a member of the executive team and report to Sheldon Koenig, President and C...
Esperion Therapeutics (ESPR) announces the appointment of Sheldon Koenig as the company's president and chief executive officer, effective immediately.Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space, the company...
-- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO -- -- Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior ...
- Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p<0.0001) - - Patients considere...
Esperion recently reported their Q1 earnings that revealed a big miss on EPS and revenue. Consequently, the share price got cut ~30% as Street analyst cut their targets. Despite having impressive clinical data, NEXLETOL and NEXLIZET have had a disappointing launch thus far. However, t...
Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. Those figures were published after market hours Tuesday, so the Wednesday fallout was ugly, with the company's stock closing 21.8% lower. In Q1 Esperion earned $8 million, over four times the $1.8 m...
Having lost more than a fifth of value so far, Esperion Therapeutics ([[ESPR]] -21.8%) is on course to mark its biggest one-day loss in nearly two years after its Q1 2021 results came below expectations.A downgrade by Stifel has added to the pressure with the analyst Derek Archila n...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...